News >

Sequential CD19- and CD22-Directed CAR T-Cell Therapy Improves Long-Term Remission in Relapsed/Refractory B-ALL

Virginia Powers, PhD
Published: Wednesday, Mar 27, 2019

blood cellsSequential administration of CAR T-cell therapy targeting both the CD19 and CD22 antigens demonstrated high complete remission (CR) rates and improved long-term survival in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) following allogeneic hematopoietic stem cell transplant (HSCT), according to findings presented at the 2019 European Society for Blood and Marrow Transplantation Annual Meeting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication